Diabetes & Obesity: Charting Pathways to Effective Co-management in Primary Care (Enduring from 20LV223)

Intended Audience: Physicians, PAs, NPs, nurses, and pharmacists

Watch this recording of a live satellite symposium at the American Academy of Family Physicians' (AAFP) 2023 Family Medicine Experience for a sneak peek at new data emerging from an innovative QI initiative examining the intersection of type 2 diabetes (T2D) and obesity in the primary care setting.

Reflecting on key findings and real-world barriers, the interactive session will facilitate discussion on practical tips and tools, including a new Diabetes and Obesity Co-Management Resource, for adopting a T2D and obesity co-management approach in the primary care setting where family medicine providers are uniquely positioned to support patients in achieving their glycemic and weight loss goals.

• Integrate weight loss as a treatment target in diabetes treatment planning for patients with T2D and obesity
• Identify appropriate patients with T2D for treatment intensification to support achievement of glycemic control and weight loss goals and improved health outcomes
• Apply current evidence in treatment decision-making, including timing of treatment intensification, for patients with diabetes and obesity to support prompt glycemic control and sustained weight loss for optimization of health outcomes
• Employ validated shared decision-making techniques into clinic workflows to engage patients with T2D in effective decision-making regarding weight loss, including communication of personalized weight loss goals and methods
• Employ evidence-based strategies and tools to support effective tracking and management of patients with T2D and obesity

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.5 contact hours (which includes 0.3 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Michelle F. Magee, MD (Course Director, Speaker)
  
  Grants / Research Support – Medtronic, Uluru
  Speakers Bureau or other Promotional Education – ADA, ADCES, PRIMED
  The relationships reported above are related to the following therapeutic area: Endocrinology and Metabolism

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Kathleen G. Reims, MD, FAAFP (Speaker)
• Ryan J Atkinson, PharmD, MBA (Moderator)
• Stephanie Joyce, PA, MSPAS, MS, RD CNSC (Reviewer)
• Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)
• Jason Welch, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.